A HPLC-MS/MS method for the determination of Nadolol in rat plasma: Development, validation, and application to pharmacokinetic study.

A sensitive validated method has been developed for the quantification of Nadolol in rat plasma by high performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) using deuterated Nadolol (Nadolol D9) as internal standard (IS). The liquid-liquid extraction method using ethyl acetate was employed for the sample pretreatment. The separation was achieved on the Agilent Zorbax XDB C18 column (150 mm × 4.6 mm ID., 3.5 µm). The column temperature was controlled at 30°C. The components were eluted by using mobile phase A (10 mM ammonium formate) and mobile phase B (acetonitrile) in the ratio of 20:80 v/v with a flow rate of 0.5 mL/min. And 15 µL aliquot was injected in an isocratic elution mode with a total run time of 2.5 min. The multiple reactions monitoring transitions, m/z 310.20/254.10 for Nadolol and IS 319.20/255.00 were selected to achieve high selective analysis. The method exhibited great selectivity and linearity over the concentration range of 6 to 3000 ng/mL. The lower limit of quantification was found to be 6 ng/mL. The developed method proved acceptable results on selectivity, sensitivity, precision, accuracy, and stability studies as per Food and Drug Administration guidelines. This HPLC-MS/MS assay was successfully applied to get the pharmacokinetics parameters in rat plasma.

In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.

BACKGROUND: Siddha Medicine is a valuable therapeutic choice which is classically used for treating viral respiratory infections, this principle of medicine is proven to contain antiviral compounds. OBJECTIVE: The study is aimed to execute the In Silico computational studies of phytoconstituents of Siddha official formulation Kabasura Kudineer and novel herbal preparation - JACOM which are commonly used in treating viral fever and respiratory infectious diseases and could be affective against the ongoing pandemic novel corona virus disease SARS-CoV-2. METHOD: Cresset Flare software was used for molecular docking studies against the spike protein SARS-CoV-2 (PDB ID: 6VSB). Further, we also conducted insilico prediction studies on the pharmacokinetics (ADME) properties and the safety profile in order to identify the best drug candidates by using online pkCSM and SwissADME web servers. RESULTS: Totally 37 compounds were screened, of these 9 compounds showed high binding affinity against SARS-CoV-2 spike protein. All the phytoconstituents were free from carcinogenic and tumorigenic properties. Based on these, we proposed the new formulation called as "SNACK-V" CONCLUSION: Based on further experiments and clinical trials, these formulations could be used for effective treatment of COVID-19.

GSK-3 Inhibitors as New Leads to Treat Type-II Diabetes.

In India as well as globally, diabetes is in a state of high risk and next to cardiovascular disease. As per the WHO, the risk of diabetes is expected to rise about 511 million by 2030. In quest of novel targets for type-2 diabetes, many targets were elucidated, such as Glycogen Synthase Kinase-3 (GSK-3), Dipeptidyl Peptidase (DPP-IV), PPAR-γ, α-Glucosidase, α-Amylase, GLP-1, and SGLT. Among the targets, GSK-3 was reported to be an effective target for the treatment of diabetes. In the metabolism of glycogen, GSK is a regulatory enzyme for the biosynthesis of glycogen (glycogenesis). It catalyzes the synthesis of a linear unbranched molecule with 1,4-α-glycosidic linkages. GSK-3 family has two isoenzymes, namely α and ß, which differ in their Nand C- terminal sequences and are semi-conservative multifunctional serine/threonine kinase enzymes. In this chapter, we discuss an overview of general diabetic mechanisms and how GSK-3 modulation may influence these processes. Mutation in the GSK-3 complex causes diabetes. Synthetic and natural scaffolds modulate GSK-3 against diabetes and leading to its optimization for the development of GSK-3 inhibitors. This review mainly focuses on the development of GSK-3 inhibitors and highlights current and potential future therapeutic approaches that support the notion of targeting glucose metabolism with novel antidiabetic agents.

Prevalence of Stroke Cases in Warangal, Telangana Region, India: A Hospital-Based Case Study.

Stroke is becoming a main cause of early death and disability in developing countries like India, and it is mostly enhanced by increased predominance of major risk factors. A detailed knowledge about the nature and magnitude of the stroke cases in this particular area is not only important for acute treatment but also it helps to prevent hospital admissions due to reoccurring stroke. The present study was conducted in the Department of Stroke at MGM Hospital, Warangal, India, to study the patterns of stroke admissions. All the collected data were compiled and analyzed using appropriate statistical tools. The mean age of study population was found to be 58.9 ± 18. Only 2.7% of stroke incidents occurred in people aged ≤40 years old, 4.9% of cases concerned people between 41 and 50 years old, 18.2% of the incidents happened when the subjects were between 51 and 60 years old, and in 74.2% of the cases, the individuals were ≥60 years old. The frequencies of ischemic (IS), subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH) in Warangal region were 57.9%, 7.3%, and 29.2%, respectively. A statistically significant association was found for both smoking (χ2 = 419.1 and p < 0.001) and alcohol (χ2 = 68.7 and p < 0.001) as risk factors in stroke. From this study, it was apparent that in Telangana region, there is a need to provide structured clinical management in treating emergency stroke cases and implement stroke care services with organized multidisciplinary teams.

Design, synthesis and biological evaluation of theophylline containing variant acetylene derivatives as α-amylase inhibitors.

A novel pharmacophore with theophylline and acetylene moieties was constructed by using a fragment-based drug design and a series of twenty theophylline containing acetylene conjugates were designed and synthesized, and all the compounds were evaluated by enzyme-based in vitro α-amylase inhibition activity. The in vitro evaluation revealed that most of the compounds displayed good inhibitory activities, and among them nine analogs 13-15, 20, 21 and 24-27 were exhibited more or nearly as equipotent inhibitory activity with IC50 values 1.11 ±â€¯0.07, 1.14 ±â€¯0.17, 1.07 ±â€¯0.01 and 1.21 ±â€¯0.03, 1.33 ±â€¯0.09, 1.17 ±â€¯0.01, 1.05 ±â€¯0.02, 1.61 ±â€¯0.04, 1.02 ±â€¯0.03 µM respectively, as compared with standard, acarbose 1.37 ±â€¯0.26 µM. Further, molecular docking simulation studies were done to identify the interactions and binding mode of synthesized analogs at binding site of α-amylase enzyme (PBD ID: 4GQR). Among the synthesized analogs, two compounds 25 and 27 were selected on the basis of α-amylase inhibition activity and evaluated for in vivo anti-diabetic activity by High Fat Diet-Streptozotocin (HFD-STZ) model in normal rats. At the dose of 10 mg/kg, bw, po these compounds have significantly reduced Plasma Glucose level in rats as compared to pioglitazone. The anti-diabetic activity results showed that the animal treated with the compounds 25 and 27 could better reverse and control the progression of the disease compared to the standard.

Antioxidant, analgesic and anti-inflammatory activities of Leucas cephalotes (Roxb. ex Roth) Spreng / As atividades antioxidantes, analgésica e anti-inflamatórios dos cephalotes Leucas (Roxb. ex Roth) Spreng

The whole plant of the methanolic extract from Leucas cephalotes was screened for invitro antioxidant (using the DPPH method), invivo analgesic (using hot plate test in mice) and anti-inflammatory (using rat paw edema test) activities. The methanolic extract of Leucas cephalotes (MELC) scavenged the DPPH radicals in a dose-dependent manner. The IC50 value to scavenge DPPH radicals was found to be 421.3µg/ml. A significant (p<0.0005) analgesic activity was observed at 60 min with 200 mg/kg, and 400 mg/kg exhibited maximum activity. The maximum anti-inflammatory response was produced at 3 hr and 2 hr with doses of 200 and 400 mg/kg, respectively. These results suggest that the methanolic extract from Leucas cephalotes exerts significant analgesic and anti-inflammatory effects, which were comparable with standard drugs.

O extrato metanólico total de Leucas cephalotes foi submetido à triagem para as atividades antioxidante in vitro (utilizando o método DPPH), analgésica (utilizando teste da placa quente, em camundongos) e antiinflamatória (utilizando teste de edema da pata de rato), nas doses de 200 e 400 mg/kg. O extrato metanólico de Leucas cephalotes (MELC) inativou radicais difenil picril hidrazila (DPPH) de forma dose-dependente. O IC50 para essa atividade foi de 421,3 µg/mL. Observou-se atividade analgésica significativa (p<0,0005) a 60 minutos, com 200 mg/kg, e, com 400 mg/kg, observou-se atividade máxima. A resposta antiinflamatória máxima foi produzida, respectivamente, em 3 h e 2 h, com doses de 200 e 400 mg/kg. Estes resultados sugerem que o extrato metanólico de Leucas cephalotes apresenta efeitos analgésico e antiinflamatório significativos, comparáveis aos fármacos padrão.